The ALSFRS-R is now established not only for clinical use to measure disease progression and patient status, but also as a standard outcome measure employed across ALS trials. 3,24 The Significance of ...

Japanese pharma major Shionogi today revealed that its board of directors has resolved to acquire a newly established company ...

Discover comprehensive details about Edaravone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") ...

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger that has shown potent antioxidant, anti-inflammatory and neuroprotective effects in variety of disease models. In this study ...

Review the side-effects of Edaravone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict ...

Please provide your email address to receive an email when new articles are posted on . Both edavarone dosing regimens produced similar safety and efficacy results. Based on study data, a staggered ...

Edaravone, a medication that scrubs cells of toxic free radicals, may help a subset of people with amyotrophic lateral sclerosis. That was the upshot of a presentation at the International Symposium ...

ALS Functional Rating Scale-Revised (ALSFRS-R) scores were similar after long-term treatment with edaravone (-0.91 points per month, 95% CI -0.69 to -1.07) or standard therapy (-0.85 points per month, ...

U.S. and Canada transaction supports continued access to RADICAVA(R) for people living with ALS while enabling Tanabe Pharma America to focus on future growth and innovation JERSEY CITY, N.J., Dec. 22 ...